Astec Lifesciences Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2016
October 27, 2016 at 09:09 am EDT
Share
Astec LifeSciences Limited reported unaudited standalone and consolidated earnings results for the second quarter and six months ended September 30, 2016. For the quarter, on standalone basis, the company reported sales/income from operations were of INR 878.525 million compared to INR 584.978 million a year ago. Profit from operations before other income, finance costs and exceptional items were of INR 194.370 million compared to INR 69.297 million a year ago. Profit from ordinary activities before tax was INR 49.324 million compared to INR 15.774 million a year ago. Net profit was INR 111.626 million or INR 5.71 per diluted share compared to INR 18.116 million or INR 0.93 per diluted share a year ago.
For six months, on standalone basis, the company reported sales/income from operations were of INR 1,563.919 million compared to INR 1,190.848 million a year ago. Profit from operations before other income, finance costs and exceptional items were of INR 274.308 million compared to INR 172.554 million a year ago. Profit from ordinary activities before tax was INR 200.233 million compared to INR 86.203 million a year ago. Net profit was INR 149.014 million or INR 7.63 per diluted share compared to INR 73.191 million or INR 3.76 per diluted share a year ago.
For the quarter, on consolidated basis, the company reported sales/income from operations were of INR 884.476 million compared to INR 664.622 million a year ago. Profit from operations before other income, finance costs and exceptional items were of INR 195.214 million compared to INR 72.743 million a year ago. Profit from ordinary activities before tax was INR 150.329 million compared to INR 18.130 million a year ago. Net profit after taxes, minority interests and share of profit/loss of associates was INR 111.994 million or INR 5.73 per diluted share compared to INR 20.355 million or INR 1.04 per diluted share a year ago.
For six months, on consolidated basis, the company reported sales/income from operations were of INR 1,569.870 million compared to INR 1,297.574 million a year ago. Profit from operations before other income, finance costs and exceptional items were of INR 275.393 million compared to INR 177.828 million a year ago. Profit from ordinary activities before tax was INR 201.479 million compared to INR 85.772 million a year ago. Net profit after taxes, minority interests and share of profit/loss of associates was INR 149.491 million or INR 7.66 per diluted share compared to INR 72.061 million or INR 3.70 per diluted share a year ago.
Astec LifeSciences Limited is an India-based company that is primarily engaged in manufacturing a range of agrochemical active ingredients and pharmaceutical intermediates. The Company operates through the Agrochemicals segment. It manufactures a range of fungicides, insecticides, herbicides, and intermediates for its global customers. The Companyâs products and intermediates includes triazole fungicides, heterocyclic herbicides, sulfonylurea herbicides, synthetic pyrethroids, alkyl and aryl magnesium halides, mixed metal halides, silane derivatives, fluorinated aromatic, aliphatic and heterocyclic intermediates, fluorinated aromatic amines, fluorinated pyridine derivatives, fluorinated aromatic carboxylic acids, fluorinated benzyl alcohols, fluorinated ketones and benzophenones, fluorinated heterocyclic mercaptans, heterocyclic mercaptans, thiopyrimidines, aromatic mercaptans, thorium salts, pyrazaloneâs and heterocyclic sulfonyl chlorides.
Astec Lifesciences Limited Reports Unaudited Standalone and Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2016